 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
95 News |  |
| «12 |
- nemiralisib (GSK2269557) / GSK
Biomarker, Trial primary completion date: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Nov 9, 2016
P2, N=35, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2016 --> Feb 2017
- || nemiralisib (GSK2269557) / GSK
Biomarker, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Sep 20, 2016
P2, N=64, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2016 --> Feb 2017 Trial primary completion date: Feb 2015 --> Aug 2015
- | nemiralisib (GSK2269557) / GSK
Trial completion, Enrollment change: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects (clinicaltrials.gov) - Sep 12, 2016
P1, N=22, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2015 --> Aug 2015 Recruiting --> Completed | N=30 --> 22
- |||| nemiralisib (GSK2269557) / GSK
Trial completion: An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jun 10, 2016
P2, N=126, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=30 --> 22 Active, not recruiting --> Completed
- nemiralisib (GSK2269557) / GSK
Enrollment open: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects (clinicaltrials.gov) - Mar 28, 2016
P1, N=30, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | nemiralisib (GSK2269557) / GSK
New P1 trial: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects (clinicaltrials.gov) - Feb 25, 2016
P1, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||| nemiralisib (GSK2269557) / GSK
Enrollment closed: An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Feb 22, 2016
P2, N=120, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- nemiralisib (GSK2269557) / GSK
Trial initiation date: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Feb 22, 2016
P2, N=5, Not yet recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Initiation date: Feb 2016 --> May 2016
- | nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment open: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Jan 6, 2016
P2, N=35, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: Feb 2016 --> May 2016 Not yet recruiting --> Recruiting
- ||| nemiralisib (GSK2269557) / GSK
Enrollment change, Trial primary completion date: An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Dec 14, 2015
P2, N=120, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=100 --> 120 | Trial primary completion date: Dec 2015 --> Apr 2016
- nemiralisib (GSK2269557) / GSK
Phase classification: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Dec 3, 2015
P2, N=5, Not yet recruiting, Sponsor: GlaxoSmithKline
N=100 --> 120 | Trial primary completion date: Dec 2015 --> Apr 2016 Phase classification: P1 --> P2
- | nemiralisib (GSK2269557) / GSK
Enrollment open: A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma (clinicaltrials.gov) - Dec 3, 2015
P2, N=50, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P1 --> P2 Not yet recruiting --> Recruiting
- nemiralisib (GSK2269557) / GSK
New P1 trial: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Nov 2, 2015
P1, N=5, Not yet recruiting, Sponsor: GlaxoSmithKline
- | nemiralisib (GSK2269557) / GSK
New P2 trial: A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma (clinicaltrials.gov) - Oct 5, 2015
P2, N=50, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||| nemiralisib (GSK2269557) / GSK
Biomarker, Trial completion, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Sep 8, 2015
P2, N=64, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Feb 2015
- | nemiralisib (GSK2269557) / GSK
Biomarker, New P2 trial: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Aug 13, 2015
P2, N=35, Not yet recruiting, Sponsor: GlaxoSmithKline
- nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment change: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Jul 13, 2015
P2, N=65, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Feb 2015 N=30 --> 65
- | nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment open, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Jun 15, 2015
P2, N=30, Recruiting, Sponsor: GlaxoSmithKline
N=30 --> 65 Active, not recruiting --> Recruiting | Trial primary completion date: Feb 2015 --> Sep 2015
- nemiralisib (GSK2269557) / GSK
Biomarker, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Jun 11, 2015
P2, N=30, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Recruiting | Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Sep 2015 --> Feb 2015
- |||| nemiralisib (GSK2269557) / GSK
Enrollment open: An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Apr 27, 2015
P2, N=100, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2015 --> Feb 2015 Not yet recruiting --> Recruiting
- | nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment closed, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Jan 26, 2015
P2, N=30, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Oct 2015
- ||||| nemiralisib (GSK2269557) / GSK
New P2 trial: An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Nov 19, 2014
P2, N=100, Not yet recruiting, Sponsor: GlaxoSmithKline
- | nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment open: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Aug 11, 2014
P2, N=30, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Oct 2015 Not yet recruiting --> Recruiting
- | nemiralisib (GSK2269557) / GSK
Biomarker, New P2 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - May 2, 2014
P2, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
- nemiralisib (GSK2269557) / GSK
Enrollment change: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects (clinicaltrials.gov) - Oct 30, 2013
P1, N=45, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=28 --> 45
- | nemiralisib (GSK2269557) / GSK
Trial completion: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects (clinicaltrials.gov) - Oct 30, 2013
P1, N=45, Completed, Sponsor: GlaxoSmithKline
N=28 --> 45 Active, not recruiting --> Completed
- | nemiralisib (GSK2269557) / GSK
New P1 trial: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects (clinicaltrials.gov) - Jan 6, 2013
P1, N=45, Completed, Sponsor: GlaxoSmithKline
- ||| nemiralisib (GSK2269557) / GSK
Trial completion: Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557 (clinicaltrials.gov) - May 23, 2012
P1, N=61, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| nemiralisib (GSK2269557) / GSK
New P1 trial: Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557 (clinicaltrials.gov) - Oct 27, 2011
P1, N=61, Completed, Sponsor: GlaxoSmithKline